NHSL3 and lung carcinoma: To test the association of KIAA1522 expression with the activation of KRAS pathway, the loss of function assays were performed in lung cancer cell lines A549 and H460, both of which express the mutant form of KRAS gene, i.e. the oncogenic KRAS.